Mirae Asset Healthcare Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 23-09-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
S&P BSE Health Care - TRI 0.82 15.56 50.49 12.54 2.73 14.27
S&P BSE SENSEX - TRI -1.97 6.89 -2.55 6.90 9.20 12.45

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 57.16 19.61 8.32 2.09 3,652.59
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 55.29 11.77 3.45 2.23 1,360.70
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 59.07 15.04 5.36 2.81 563.44

Fund Holdings as on 31-August-2020

  • Sun Pharmaceutical Industries Limited

  • Dr. Reddy's Laboratories Limited

  • Divi's Laboratories Limited

  • Cipla Limited

  • IPCA Laboratories Limited

  • Lupin Limited

  • Aurobindo Pharma Limited

  • Torrent Pharmaceuticals Limited

  • Laurus Labs Limited

  • Biocon Limited

  • Apollo Hospitals Enterprise Limited

  • Ajanta Pharma Limited

  • Dr. Lal Path Labs Limited

  • Syngene International Limited

  • Abbott India Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Rossari Biotech Limited

  • SRF Limited

  • Max Financial Services Limited

  • Alkem Laboratories Limited

  • HDFC Life Insurance Company Limited

  • Tata Chemicals Limited

  • Sanofi India Limited

  • SBI Life Insurance Company Limited

  • Vinati Organics Limited

  • Tri Party Repo

  • Neogen Chemicals Limited

  • Natco Pharma Limited

  • Mirae Asset Cash Management Fund - DIRECT GROWTH

  • Cadila Healthcare Limited

  • Net Receivables / (Payables)

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Chemicals

  • Insurance

  • Miscellaneous

  • Diversified

  • Finance - Others

View More

Fund Manager

  • Cash

  • Equity

  • MFU

View More

About Mirae Asset Healthcare Fund

Scheme Analysis

Mirae Asset Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Mirae Asset Mutual Fund. It was launched on 02-Jul-2018 and currently has an AUM of ₹876.08 crore. Mirae Asset Healthcare Fund is benchmarked against S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Mirae Asset Healthcare Fund ended down ₹-0.21(-1.22%)yesterday to ₹16.979.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Mirae Asset Healthcare Fund is managed by Vrijesh Kasera .

Fund House Contact

Unit 606, 6th Floor, Windsor, Off CST Road, Kalina, Santacruz (E), Mumbai - 400 098

022-67800300
022-67253942